CAJ | 학술논문

目的系统评价复方苦参注射液(CKI)对中晚期肝癌的疗效和安全性.方法计算机检索中文期刊全文数据库、中文科技期刊全文数据库、万方医学网和PubMed,检索时间至2014年11月,纳入单独常规支持治疗比较联合复方苦参注射液治疗中晚期肝癌的随机对照研究.根据Co-chrane协作网推荐的偏倚风险评估文献质量,采用Review Manager 5.3进行分析.以近期疗效、疼痛疗效有效率为效应指标.结果纳入8篇RCTs共472例患者.Meta分析结果显示,治疗组近期疗效有效率更高(P=0.008),治疗组肝癌患者疼痛缓解的有效人数高于对照组(P＜0.01),未观察到明显不良反应.结论复方苦参注射液对中晚期肝癌是一种有效的、安全的辅助药物.
목적 계통평개복방고삼주사액(CKI)대중만기간암적료효화안전성.방법 계산궤검색중문기간전문수거고、중문과기기간전문수거고、만방의학망화PubMed,검색시간지2014년11월,납입단독상규지지치료비교연합복방고삼주사액치료중만기간암적수궤대조연구.근거Co-chrane협작망추천적편의풍험평고문헌질량,채용Review Manager 5.3진행분석.이근기료효、동통료효유효솔위효응지표.결과 납입8편RCTs공472례환자.Meta분석결과현시,치료조근기료효유효솔경고(P=0.008),치료조간암환자동통완해적유효인수고우대조조(P＜0.01),미관찰도명현불량반응.결론 복방고삼주사액대중만기간암시일충유효적、안전적보조약물.
Objective To investigate the efficacy and safety of compound kushen injection (CKI)in the treatment for patients with advanced liver cancers.Methods Relevantly randomized controlled trials from China National Knowledge Infrastructure (CNKI),Chinese Science and Technology Journal Database (VIP),Wanfang Data,and Pubmed were searched until November,2014.Randomized controlled trials (RCTs) of supportive care compared with combined therapy of CKI in the treatment for patients with advanced liver cancers were included.The methodological quality of RCTs was assessed independently with bias risk according to the Cochrane collaboration.All data were analyzed with the Review Manager 5.3.Results Eight RCTs involving 472 patients were included.The meta-analysis results suggested that the shortterm efficacy of the treatment group be higher (P =0.008) and that the pain relief be a significant benefit in the treatment group (P ＜0.01).Adverse reactions were not observed.Conclusions CKI is an effective and safe adjuvant drug for advanced liver cancers.